Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer

  • P. O’Shea
  • M. Cassidy
  • R. Freaney
  • P. McCarthy
  • J. Fennelly
Article

Abstract

An enzyme immunoassay for serum neuron-specific enolase (NSE) was evaluated with respect to analytical performance and clinical utility and compared with immunohistochemical evaluation of neuroendocrine differentiation. Values obtained agreed well with values obtained using a radioimmunoassay method giving a correlation coefficient of 0.934. Analytical performance of the enzyme immunoassay was good but the diagnostic sensitivity of 82 % in extensive and 67% in limited disease was insufficient for serum NSE to be of value in the diagnosis of small cell lung cancer (SCLC). Serum NSE decreased significantly in 11 of 15 patients with SCLC following institution of chemotherapy. Classification of lung cancers into SCLC and non small cell lung cancer (NSCLC) types is largely based on tumour morphology. Neuroendocrine differentiation may not be morphologically evident. Immunohistochemical staining of tumour tissue with markers of neuroendocrine differentiation, i.e. NSE (both monoclonal and polyclonal antibodies) Leu 7, Chromogranin A and P G P 9.5 was performed in both patients with SCLC and NSCLC. 38 per cent of patients with NSCLC had both raised serum NSE and positive NSE (polyclonal) immunoperoxidase staining of lung tissue. A further 35 per cent of patients showed a raised serum NSE or positive immunohistochemistry but not both. The presence of two positive immunoperoxidase markers in lung tissue has been suggested as an indicator of responsiveness to chemotherapy in NSCLC patients. A number of factors may affect immunohistochemical positivity in tissue sections and the additional use of a serum marker may better define chemotherapy responsive groups.

References

  1. 1.
    Carney, D. N., Marangos, P. J. Ihdedc, Bunn, P. A. et al. Serum Neuron-Specific Enolase; a marker for disease extent and response to therapy of small cell lung cancer. The Lancet 1982; 13: 583–586.CrossRefGoogle Scholar
  2. 2.
    Lamb, D. Lung cancer and its classification. Anthony, P. P. and McSweeney, W. W. (Eds). Recent Advances in Histopathology. No. 13 Churchill Livingstone/RNM Edinburgh 1987; 13: 45–59.Google Scholar
  3. 3.
    Baylin, S. B. Neuroendocrine differentiation: A prognostic feature of non-small cell cancer. J. Clin. Oncol. 1989; 7: 1375–1376.PubMedGoogle Scholar
  4. 4.
    Addis, B. J. Hamid, Q., Ibrahim, N. B., Fahey, M., Bloom, S. R., Polak, J. M. Immunohistochemical markers of small cell carcinoma and related neuroendocrine tumours of the lung. J. Pathol. 1987; 153: 137–150.PubMedCrossRefGoogle Scholar
  5. 5.
    Visscher, D. W., Zarbo, R. J., Trojonawski, J. Q., Sakr, W., Crissman, J. D. Neuroendocrine differentiation on poorly differentiated lung carcinoma; a light microscopic and immunohistologic study. Mod. Pathol. 1990; 153: 508–512.Google Scholar
  6. 6.
    Bergh, J., Esscher, T., Steinholtz, L. et al. Immunocytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. Am. J. Clin. Pathol. 1985; 84: 1–7.PubMedGoogle Scholar
  7. 7.
    Linnoila, R. I., Mulshine, J. L., Steinberg, S. M. et al. Neuroendrine differentiation in endocrine and nonendocrine lung carcinomas. Am. J. Clin. Pathol. 1988; 90: 641–652.PubMedGoogle Scholar
  8. 8.
    Crompton, G. Small Cell Lung Cancer. BMJ 1990; 3000: 201–210.Google Scholar
  9. 9.
    Souhami, R.L. Neuroendocrine phenotype,chemosensitivity and prognosis in adenocarcinoma of the lung. Ann. of Oncol, 1991; 2: 323–324.Google Scholar
  10. 10.
    Graziano, S. L., Mazid, R., Newman, N. et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non small cell lung cancer. J. Clin. Oncol. 1989; 7: 1398–1406.PubMedGoogle Scholar
  11. 11.
    Jorgensen, L. G. M., Hirsch, F. R., Skov, B. G. Osterlind, K., Cooper, E. H., Larsson, L. I. Occurence of neuronspecific enolase in tumour tissue and serum in small cell lung cancer. Br. J. Cancer. 1991; 63: 151.PubMedGoogle Scholar
  12. 12.
    Reidy, J. A., Skoczenski, B. A., Bleile, D. M., Usategui, M. An enzyme immunoassay for the detection of gamma-enolase in serum. Clin. Chem. 1987; 33: 928–929.Google Scholar
  13. 13.
    Cooper, E. H., Splinter, T. W. A., Brown, D. A., Muers, M. F., Peake, M. D., Pearson, S. L. Evaluation of a radioimmunoassay for Neuron Specific Enolase in Small Cell Lung Cancer. Br. J. Cancer 1985; 52: 333–338.PubMedGoogle Scholar
  14. 14.
    Hsu, S. M., Raine, L., Fanger, H. Use of Avidin-Biotin Peroxidase Complex (ABC) in immunohistochemical techniques. J. Histochem. Cytochem. 1981; 29: 577–580.PubMedGoogle Scholar
  15. 15.
    Johnson, D. H., Marangos, P. J., Forbes, J. et al. Potential utility of Neuron Specific Enolase levels in small cell carcinomas of the lung. Cancer Research 1984; 44: 5409–5414.PubMedGoogle Scholar
  16. 16.
    Akoun, G. M., Scarna, H. M., Milleron, B. J., Benichou, M. P. Herman, D. P. Serum Neuron Specific Enolase a marker for disease extent and response to therapy for small cell lung cancer. Chest 1985; 87: 39–49.PubMedCrossRefGoogle Scholar
  17. 17.
    Splinter, T. A., Cooper, E. H., Kho, G. H., Oosteron, R., Peake, M. D. Neuron Specific Enolase as a guide to the treatment of small cell lung cancer. Eur. J. Cancer Clin. Oncol. 1987; 23: 171–176.PubMedCrossRefGoogle Scholar
  18. 18.
    Burghuber, O. C., Worofka, B., Schernthanerg, G. et al. Serum Neuron Specific Enolase is a useful tumour marker for small cell lung cancer. Cancer 1990; 65: 1386–1390.PubMedCrossRefGoogle Scholar
  19. 19.
    Teeling, M., McGing, P., Johnston, P., Carney, D. N. Clinical correlation of tumour endocrine markers in lung cancer. In: Hansen, H. H. (Eds) Basic and clinical concepts of lung cancer. Kluwer Academic Publishers 1989, chapter 9.Google Scholar
  20. 20.
    Carney, D. N. Biology of small cell lung cancer. The Lancet 1992; 339: 843–845.CrossRefGoogle Scholar
  21. 21.
    Esscher, T., Steinholtz, L., Bergh, T., Nou, E., Nilsson, K., Pahlman, S. Neuron Specific Enolase: A useful diagnostic serum marker for small cell carcinoma of the lung. Thorax. 1985; 40: 85–90.PubMedGoogle Scholar
  22. 22.
    Beasteall, G. H., Cooke, B., Rustin, G. J. S. et al. A review of the role of established tumour markers. Ann. Clin. Chem. 1991; 28: 5–18.Google Scholar
  23. 23.
    Van Zandwijk, N., Jassem, E., Bonfrer, J. M. G. et al. Value of Neuronspecific enolase in early detection of relapse in small cell lung carcinoma. Eur. J. Cancer, 1990; 26: 373–376.PubMedCrossRefGoogle Scholar
  24. 24.
    Jorgensen, L. G. M., Osterlind, K., Hansen, H. H. et al. The prognostic influence of serum neuron-specific enolase in small cell lung cancer. Br. J. Cancer 1988; 58: 805–807.PubMedGoogle Scholar
  25. 25.
    Said, J. W., Vimadalal, S., Nash, G. et al. Immunoreactive neuronspecific enolase, bombesin and chromogranin as markers for neuroendocrine lung tumours. Hum. Pathol. 1985; 16: 236–240.PubMedCrossRefGoogle Scholar
  26. 26.
    Watts, A. E., Said, J. W., Shintaku, I. P. et al. Chromogranin as a marker of neuroendocrine cells in cytologie material: An immunochemical study. Am. J. Clin. Pathol. 1985; 84: 273–277.Google Scholar
  27. 27.
    Bordi, C., Pilatio, F. P., D’Adda, T. Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours. Virchows Archiv-A-Pathol. Anat. 1988; 413: 387–398.CrossRefGoogle Scholar
  28. 28.
    Thomas, P., Battifora, H., Mandenno, G.L.etal. Amonoclonal antibody against neuron-specific enolase. Am. J. Clin. Pathol. 1987; 88: 146–152.PubMedGoogle Scholar
  29. 29.
    Dhillon, A. P., Rode, J., Dhillon, D. P. et al. Neural markers in carcinoma of the lung. Br. J. Cancer 1985; 51: 645–652.PubMedGoogle Scholar
  30. 30.
    Harding, M., McAllister, J., Mulkis, G. et al. Neuronspecific enolase (NSE) in small cell lung cancer: A tumour marker of prognostic significance. Br. J. Cancer 1990; 61: 605–6PubMedGoogle Scholar
  31. 31.
    Skov, B. G., Sorensen, J. B., Hirsch, F. R. et al. Prognostic impact of histological demonstration of chromogranin A and neuron-specific enolase in pulmonary adenocarcinoma. Ann. Oncol. 1991; 2: 355–360.PubMedGoogle Scholar

Copyright information

© Springer 1995

Authors and Affiliations

  • P. O’Shea
    • 1
  • M. Cassidy
    • 2
  • R. Freaney
    • 3
  • P. McCarthy
    • 2
  • J. Fennelly
    • 4
  1. 1.Department of BiochemistrySt. Vincent’s HospitalDublin
  2. 2.Department of HistologySt. Vincent’s HospitalDublin
  3. 3.Department of MetabolismSt. Vincent’s HospitalDublin
  4. 4.Department of OncologySt. Vincent’s HospitalDublin

Personalised recommendations